AIM ImmunoTech Inc’s filing revealed that its CEO & President Equels Thomas K acquired Company’s shares for reported $6730.0 on Mar 05 ’25. In the deal valued at $0.13 per share,50,000 shares were bought. As a result of this transaction, Equels Thomas K now holds 1,858,029 shares worth roughly $0.22 million.
Then, Equels Thomas K bought 44,000 shares, generating $5,060 in total proceeds. Upon buying the shares at $0.12, the CEO & President now owns 1,808,029 shares.
Before that, Equels Thomas K bought 83,334 shares. AIM ImmunoTech Inc shares valued at $10,000 were divested by the CEO & President at a price of $0.12 per share. As a result of the transaction, Equels Thomas K now holds 1,764,029 shares, worth roughly $0.21 million.
Price Performance Review of AIM
On Tuesday, AIM ImmunoTech Inc [AMEX:AIM] saw its stock fall -0.79% to $0.12. Over the last five days, the stock has gained 1.30%. AIM ImmunoTech Inc shares have fallen nearly -36.87% since the year began. Nevertheless, the stocks have fallen -67.45% over the past one year. While a 52-week high of $0.62 was reached on 01/07/25, a 52-week low of $0.11 was recorded on 02/25/25. SMA at 50 days reached $0.1739, while 200 days put it at $0.2716.
Levels Of Support And Resistance For AIM Stock
The 24-hour chart illustrates a support level at 0.1157, which if violated will result in even more drops to 0.1063. On the upside, there is a resistance level at 0.1347. A further resistance level may holdings at 0.1443. The Relative Strength Index (RSI) on the 14-day chart is 38.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0028, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.98%. Stochastics %K at 36.23% indicates the stock is a holding.
